ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Anika Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$20.22+0.24 (+1.20%)

Close on Oct 19, 2026

Market cap: $277.36M
P/E (TTM): –
Dividend yield: –

Anika Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	113	120	121	114	148	130	115	106	113	103	93	106	75	71	65	56	40
Cost of Revenue	49	44	38	41	65	61	29	31	27	24	21	21	23	29	27	24	14
Gross Profit	64	76	83	73	83	69	86	74	86	79	72	85	52	42	38	32	26
Research & Development	26	26	22	18	27	23	17	18	19	11	8.99	8.14	7.06	5.39	6.17	6.87	8.18
Selling, General & Admin	49	56	60	51	74	60	35	34	22	18	15	15	13	15	18	17	11
Total Costs & Expenses	75	81	82	70	80	97	52	53	68	53	45	44	42	52	51	48	35
Operating Income	-11	-5.10	0.84	3.67	2.62	-28	34	22	46	51	48	61	33	20	14	7.54	5.59
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	-0.29	2.54	–	–	–
Asset Impairment Charges	–	–	62	0	0	43	0	0	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	-0.01	0.03	0.37	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0.17	-2.86	-1.92	0	-0.99	-0.27	-0.93	-0.15	-0.15	–	–	–	0.13	–	–	–	–
Pretax Income	-9.31	-2.76	3.16	4.32	2.43	-29	36	23	46	51	48	62	32	20	14	7.34	5.51
Income Tax Expense	0.67	6.06	6.60	2.12	-1.71	-4.64	8.93	4.49	14	18	17	23	12	7.77	5.32	3.03	1.82
Income from Continuing Operations	-9.98	-8.83	-3.44	2.20	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	-0.90	-48	-79	-17	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-11	-56	-83	-15	4.13	-24	27	19	32	33	31	38	21	12	8.47	4.32	3.69
EPS (Basic)(per share)	-0.76	-3.83	-5.64	-1.02	0.29	-1.69	1.93	1.30	2.18	2.22	2.06	2.61	1.46	0.89	0.65	0.34	0.32
EPS (Diluted)(per share)	-0.76	-3.83	-5.64	-1.02	0.28	-1.69	1.89	1.27	2.11	2.15	2.01	2.51	1.39	0.82	0.62	0.32	0.32
Shares Outstanding (Basic, Weighted)(shares)	14	15	15	15	14	14	14	14	15	15	15	15	14	13	13	13	11
Shares Outstanding (Diluted, Weighted)(shares)	14	15	15	15	15	14	14	15	15	15	15	15	15	14	14	14	12
EBITDA	-5.68	1.78	7.28	10	9.10	-22	39	28	50	54	52	66	37	24	18	11	6.88

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 62.2%
Operating margin: -4.2%
Net margin: -3.1%
Return on equity, FY2025: -7.3%

Financial strength

Current ratio: 4.48
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 173.4%

Valuation

P/E ratio: –
Price to sales: 2.30
Price to book: 2.02
Dividend yield: –